Get the Stockscreener App
0.6713
3.52%
-0.0245
After Hours:
.62
-0.0513
-7.64%
Cytosorbents Corp stock is traded at $0.6713, with a volume of 60,600.
It is down -3.52% in the last 24 hours and down -5.54% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.6958
Open:
$0.66
24h Volume:
60,600
Relative Volume:
0.68
Market Cap:
$42.16M
Revenue:
$34.35M
Net Income/Loss:
$-10.59M
P/E Ratio:
-3.535
EPS:
-0.1899
Net Cash Flow:
$-10.14M
1W Performance:
+3.26%
1M Performance:
-5.54%
6M Performance:
-27.51%
1Y Performance:
-35.45%
1-Day Range:
$0.6115
$0.6955
1-Week Range:
$0.60
$0.75
52-Week Range:
$0.60
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.6713 | 43.70M | 34.35M | -10.59M | -10.14M | -0.1899 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents (CTSO) Reports Record Sales Growth in 2025 - GuruFocus
Earnings call transcript: CytoSorbents reports Q4 2025 earnings miss, shares dip - Investing.com
CytoSorbents Corp (NASDAQ:CTSO) Reports Q4 2025 Earnings Miss, Stock Declines - ChartMill
CytoSorbents (CTSO) Reports Slight Revenue Increase and Strategi - GuruFocus
CytoSorbents: Q4 Earnings Snapshot - 10TV
CYTOSORBENTS ($CTSO) Releases Q4 2025 Earnings - Quiver Quantitative
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - PR Newswire
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Cytosorbents (CTSO) Expected to Announce Earnings on Monday - Defense World
If You Invested $1,000 in Cytosorbents Corp (CTSO) - Stock Titan
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Fidelity
Aug Drivers: How does Cytosorbents Corporation score in quality rankingsMarket Growth Summary & Safe Capital Growth Plans - baoquankhu1.vn
CytoSorbents Corp Stock (ISIN: US23283M1018) Faces Analyst Hold Amid Massive Upside Potential - AD HOC NEWS
Cytosorbents CorporationCommon Stock (Nasdaq:CTSO) Stock Quote - The Chronicle-Journal
CytoSorbents (CTSO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
CTSO PE Ratio & Valuation, Is CTSO Overvalued - Intellectia AI
Aug Fed Impact: Will Cytosorbents Corporation benefit from government policy2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - BioSpace
CTSO SEC FilingsCytosorbents Corp 10-K, 10-Q, 8-K Forms - Stock Titan
CTSO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CTSO.O PE Ratio & Valuation, Is CTSO.O Overvalued - Intellectia AI
Travel Stocks: What makes Cytosorbents Corporation stock attractive today2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
Head to Head: Cytosorbents vs. Futureworld - National Today
Investment Report: Can Brookfield Business Partners LP Limited Partnership keep up with sector leadersInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance
Avenir reports 8.3% Cytosorbents (CTSO) ownership stake in 13G/A - Stock Titan
Aug Final Week: Is WaFd Inc stock undervalued right nowDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug PreEarnings: What makes Cytosorbents Corporation stock attractive today2025 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
Rally Mode: Is Cytosorbents Corporation stock forming a cup and handleJuly 2025 Closing Moves & Trade Opportunity Analysis - baoquankhu1.vn
Trading Recap: What is CFBKs 5 year growth outlookQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Insider Buy: What is the earnings history of Cytosorbents CorporationMarket Sentiment Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update - BioSpace
CTSO Receives Continued 'Buy' Rating from D. Boral Capital | CTS - GuruFocus
CytoSorbents reports Q4 and full-year 2025 revenue expectations - Investing.com
CTSO Anticipates Improved Gross Margin for Full-Year - GuruFocus
Is Cytosorbents Corporation stock supported by strong fundamentalsMarket Growth Report & Verified Swing Trading Watchlists - ulpravda.ru
What hedge fund activity signals for Cytosorbents Corporation stockCEO Change & Comprehensive Market Scan Insights - ulpravda.ru
What is the fair value of Cytosorbents Corporation stock nowJuly 2025 Selloffs & Reliable Momentum Entry Alerts - ulpravda.ru
Reviewing Omeros (NASDAQ:OMER) and Cytosorbents (NASDAQ:CTSO) - Defense World
Can Cytosorbents Corporation stock deliver sustainable ROE2025 Price Action Summary & Verified Swing Trading Watchlists - ulpravda.ru
Does Cytosorbents Corporation stock trade at a discount to peersEarnings Risk Report & Consistent Profit Trade Alerts - ulpravda.ru
Trend Review: Will Cytosorbents Corporation stock maintain growth story2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Улправда
Can Cytosorbents Corporation stock rebound after recent weakness2025 Biggest Moves & Risk Managed Investment Strategies - Улправда
Cytosorbents (NASDAQ:CTSO) Receives “Buy” Rating from D. Boral Capital - Defense World
CTSO: D. Boral Capital Reaffirms Buy Rating and $10 Price Target - GuruFocus
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - PR Newswire
CytoSorbents (NASDAQ: CTSO) to review $37.0M sales, DrugSorb-ATR in Dec. 15 virtual fireside chat - Stock Titan
Cytosorbents (NASDAQ:CTSO) & BioLife Solutions (NASDAQ:BLFS) Financial Comparison - Defense World
How analysts rate Cytosorbents Corporation stock todayPortfolio Update Summary & Safe Capital Investment Plans - Newser
Can Cytosorbents Corporation (HQE1) stock sustain double digit ROEJuly 2025 Recap & Long-Term Safe Investment Ideas - Newser
What technical patterns form on Cytosorbents Corporation (HQE1) stock chartsVolume Spike & Real-Time Stock Price Movement Reports - Newser
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):